Founded in 2002, Tianjin Huairen Pharmaceutical Co., Ltd. located in Xiqing Economic Development Zone, Ttianjin, is a modern pharmaceutical enterprise integrating scientific research, production and sales. Currently, it is a high-tech pharmaceutical enterprise and a small and medium-sized scientific and technological enterprise recognized by the scientific and technological committee of Tianjin. The company has 6 shareholders including Haina Yangguang (Beijing) Pharmaceutical Holdings Co., Ltd., Tianjin Science and Technology Iinvestment Group Co., Ltd., Hematology Institute of Chinese Academy of Medical Sciences. Since its establishment, the company has been adhering to the business philosophy of "quality first, credit first". Over the years, the qualified rate of market sampling has reached 100%, and it has been honored by Tianjin market and quality supervision and management committee for consecutive years as "A level enterprise in quantitative and classified management of drug production", "assured drug factory" and other titles. It successfully passed the new GMP certification in 2014.

Till now, the company mainly produces bulk drugs, tablets, capsules, granules and other dosage forms. The company has Gliclazide Modified Release Tablets, IronDextranTatbles, Telmisartan tablet, Simvastatin tablet, Urbesartan hydrochlorothiazide dispersible tablets and so on more than 10 kinds of products. Among the domestic similar manufacturers, dextran iron sheet has the advantages of self-produced API, multi-specification, steady growth in sales, in the forefront of the decade.Telmisartan tablets is the largest selling product of our company at present. Over the years, we have accumulated a loyal drug population and achieved good performance in pharmaceutical enterprises of the same size.

In order to achieve faster and better development of the company, Hairen Pharmaceutical is committed to the introduction of strong strategic investors. In 2013, Haina Yangguang successfully invested in the company and became the largest shareholder of Huairen through the equity transfer in early 2018. Huairen company will integrate resources, strengthen technology and management innovation, break through bottlenecks and achieve steady development.